Ticker Group $DYNT, $ANGO, $AMEH, $OPRX: Physicians Group Companies Surge +4.41% in Weekly Performance
For the Physicians group companies, which include DYNT (Dynatronics), ANGO (AngioDynamics), AMEH (Apollo Medical Holdings), and OPRX (OptimizeRx), the past week has been marked by a significant increase in performance, with a collective gain of +4.41%. However, a deeper look into various indicators and metrics suggests a challenging road ahead for these stocks.
The Theme and Group of Tickers
The Physicians group companies represent a collection of healthcare-related stocks that have recently experienced a notable increase in performance. This group comprises DYNT, ANGO, AMEH, and OPRX, all of which are engaged in various aspects of the healthcare industry. While their recent performance is noteworthy, it is essential to consider other factors that might affect their future prospects.
Stock Outlook and Aroon Indicator
As of the latest data, these stocks carry a Negative Outlook, a sentiment backed by the Aroon Indicator. This indicator, a popular technical analysis tool, suggests that the current trend for these stocks might not be favorable. It's worth noting that technical indicators like the Aroon Indicator are just one piece of the puzzle when evaluating stocks.
Stock Fear & Greed Index
The Stock Fear & Greed Index, provided by Tickeron, indicates a negative outlook for this group. Tickeron predicts a further decline of more than 4.00% within the next month, with an 81% likelihood. This pessimistic forecast underscores the uncertainty surrounding these stocks. During the last month, the daily ratio of advancing to declining volumes for this group was 1 to 1.84, indicating a mixed sentiment among investors.
TrendMonth Indicator
Four stocks within this group exhibit a similar negative trend based on the TrendMonth indicator, with an average likelihood of 79%. This indicator suggests that the negative sentiment is widespread across the group, further highlighting the challenges these companies face.
Market Cap
The market capitalization of the Physicians Theme averages around $469.8 million. Within this group, market caps range from $2.8 million for DYNT to $1.5 billion for AMEH. This substantial variation in market capitalization reflects the diversity of companies within the theme, with AMEH being the highest valued and DYNT the lowest.
High and Low Price Notable News
In terms of price movements, DYNT experienced the highest weekly price growth at 7.02%, while AMEH faced the most significant fall at 3.04%. Such price fluctuations in the healthcare sector can be influenced by various factors, including industry-specific news, regulatory changes, and economic conditions.
Volume Trends
Volume trends are also a crucial aspect of stock analysis. While the average weekly volume growth for these stocks was 7.93%, the average monthly and quarterly volume growth rates were -29.88% and -62.48%, respectively. These figures indicate varying levels of investor interest and activity in these stocks over different timeframes.
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows:
- Valuation Rating: 71
- P/E Growth Rating: 48
- Price Growth Rating: 87
- SMR Rating: 87
- Profit Risk Rating: 93
- Seasonality Score: -15
These ratings give investors a snapshot of how these companies are fundamentally positioned, with a particular focus on valuation, profitability, and growth potential.
Individual Stock Analysis
-
ANGO's Indicator enters downward trend: The Aroon Indicator for ANGO has entered a downward trend, suggesting potential downside. Tickeron's analysis indicates an 84% probability of a downward move.
-
OPRX's Indicator enters downward trend: Similarly, the Aroon Indicator for OPRX signals a potential downward trend, with an 84% probability of a decline.
-
DYNT's RSI Oscillator climbs out of oversold territory: DYNT's RSI Oscillator has moved out of oversold territory, suggesting a possible shift from a downward to an upward trend. Tickeron's analysis indicates a 90% probability of an upward move.
In summary, while the Physicians group companies have recently shown a positive uptick in performance, there are several warning signs, including technical indicators and negative sentiment, that suggest potential challenges in the near future. Investors should exercise caution and conduct thorough research before making any investment decisions in these stocks, considering both short-term and long-term prospects. The healthcare sector, like any other, is subject to a complex web of factors that can influence stock performance, making comprehensive analysis crucial for informed decision-making.
OPRX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for OPRX moved out of oversold territory on November 21, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for OPRX just turned positive on November 28, 2025. Looking at past instances where OPRX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OPRX advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
OPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on OPRX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
OPRX moved below its 50-day moving average on November 06, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OPRX crossed bearishly below the 50-day moving average on November 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for OPRX entered a downward trend on November 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.345) is normal, around the industry mean (21.641). OPRX's P/E Ratio (1538.000) is considerably higher than the industry average of (107.160). OPRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.428). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (2.650) is also within normal values, averaging (66.682).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products
Industry ServicestotheHealthIndustry
Advertisement